Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID G TRUE

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1609854769
CMS profile
344802
Location
SPRINGFIELD, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$2,890.99

144 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,671.84 140
Education $219.15 4

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID G TRUE

NPI 1609854769 · CMS profile ID 344802

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SPRINGFIELD, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609854769?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID G TRUE, NPI 1609854769, CMS profile ID 344802. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609854769?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). DAVID G TRUE, NPI 1609854769, CMS profile ID 344802. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609854769?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
DAVID G TRUE, NPI 1609854769, CMS profile ID 344802, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1609854769?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

144 matching records · $2,890.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 144 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 144.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $12.9408/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917965683 CMS
Exeltis, USA Inc. $22.2308/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947120561 CMS
Biohaven Pharmaceutical Holding Company Ltd. $17.0508/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923757521 CMS
Lundbeck LLC $17.4407/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945810219 CMS
ABBVIE INC. $8.0007/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892553713 CMS
Janssen Scientific Affairs, LLC $23.3407/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887225873 CMS
UCB, Inc. $20.3507/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965199091 CMS
Amgen Inc. $15.4907/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939183611 CMS
Mallinckrodt Hospital Products Inc. $22.1307/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937529971 CMS
Janssen Biotech, Inc. $13.5907/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886097813 CMS
Amgen Inc. $15.8707/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939183627 CMS
Lilly USA, LLC $7.1007/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917992319 CMS
Mallinckrodt Hospital Products Inc. $124.8407/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937529969 CMS
GENZYME CORPORATION $18.6107/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938878829 CMS
Amgen Inc. $19.2206/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939183641 CMS
Biohaven Pharmaceutical Holding Company Ltd. $14.5806/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923757519 CMS
Amgen Inc. $6.5106/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939183609 CMS
Horizon Therapeutics plc $16.5806/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937706849 CMS
UCB, Inc. $19.6606/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965199089 CMS
Lilly USA, LLC $14.5806/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918047599 CMS
Janssen Biotech, Inc. $15.0806/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886097825 CMS
ABBVIE INC. $13.1406/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892553711 CMS
Amgen Inc. $10.8106/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933774895 CMS
Amgen Inc. $19.0906/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939183601 CMS
Biohaven Pharmaceutical Holding Company Ltd. $17.5706/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923757517 CMS
Janssen Biotech, Inc. $20.6405/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886097801 CMS
PFIZER INC. $13.7005/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949157351 CMS
Lundbeck LLC $13.2405/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945810217 CMS
Mallinckrodt Hospital Products Inc. $16.9505/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937529965 CMS
Mallinckrodt Hospital Products Inc. $89.0005/23/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937529967 CMS
Amgen Inc. $16.3005/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939183599 CMS
Novartis Pharmaceuticals Corporation $19.4005/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894424213 CMS
UCB, Inc. $16.5705/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908024707 CMS
Lilly USA, LLC $17.7005/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918003443 CMS
Lilly USA, LLC $0.4105/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918003447 CMS
AstraZeneca Pharmaceuticals LP $6.0305/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915320915 CMS
Novartis Pharmaceuticals Corporation $11.9905/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894424215 CMS
ABBVIE INC. $24.6005/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892553709 CMS
Amgen Inc. $22.3205/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939183639 CMS
Lilly USA, LLC $12.4605/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917974479 CMS
Biohaven Pharmaceutical Holding Company Ltd. $13.3005/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923757515 CMS
Amgen Inc. $19.1705/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939183597 CMS
AstraZeneca Pharmaceuticals LP $97.2904/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915201003 CMS
ABBVIE INC. $5.9504/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892553707 CMS
Janssen Biotech, Inc. $14.7304/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886097847 CMS
Janssen Biotech, Inc. $20.0604/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886097783 CMS
Janssen Biotech, Inc. $0.8904/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 886097789 CMS
ABBVIE INC. $6.9404/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892553705 CMS
ABBVIE INC. $14.8804/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892553703 CMS
AstraZeneca Pharmaceuticals LP $24.9904/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914876989 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,005.99 93
PY2020 $8,186.64 58
PY2021 $1,865.24 105
PY2022 $2,890.99 144
PY2023 $2,842.59 73
PY2024 $4,498.59 37
PY2025 $79.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,624,647.65 313
PY2024 Recipient $44,530.92 19
PY2024 Principal investigator $3,840,123.26 288
PY2023 Recipient $112,605.55 31
PY2023 Principal investigator $2,598,857.68 269
PY2022 Recipient $7,505.00 7
PY2022 Principal investigator $2,504,799.06 333
PY2021 Recipient $634.11 2
PY2021 Principal investigator $2,564,220.46 258
PY2020 Recipient $14,921.00 4
PY2020 Principal investigator $1,768,323.11 181
PY2019 Recipient $4,791.63 2
PY2019 Principal investigator $839,871.40 129

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

313 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $294.00 12/31/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228738432
Principal investigator 1 ModernaTX, Inc. $54.64 12/29/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975717
Principal investigator 1 ModernaTX, Inc. $61.47 12/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975709
Principal investigator 1 PFIZER INC. $107.59 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228705456
Principal investigator 1 PFIZER INC. $14.25 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706033
Principal investigator 1 PFIZER INC. $103.20 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706048
Principal investigator 1 PFIZER INC. $89.02 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706053
Principal investigator 1 PFIZER INC. $86.32 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706056
Principal investigator 1 PFIZER INC. $125.48 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706184
Principal investigator 1 PFIZER INC. $9.25 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706190
Principal investigator 1 PFIZER INC. $125.48 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706281
Principal investigator 1 PFIZER INC. $86.32 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706284
Principal investigator 1 PFIZER INC. $89.02 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706289
Principal investigator 1 PFIZER INC. $86.32 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706292
Principal investigator 1 PFIZER INC. $9.25 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706294
Principal investigator 1 PFIZER INC. $51.56 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706298
Principal investigator 1 PFIZER INC. $76.88 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706405
Principal investigator 1 PFIZER INC. $98.81 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706409
Principal investigator 1 PFIZER INC. $14.25 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706412
Principal investigator 1 PFIZER INC. $51.56 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706416
Principal investigator 1 PFIZER INC. $107.59 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706422
Principal investigator 1 PFIZER INC. $14.25 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706425
Principal investigator 1 PFIZER INC. $76.88 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706573
Principal investigator 1 PFIZER INC. $103.20 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706578
Principal investigator 1 PFIZER INC. $103.20 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706581
Principal investigator 1 PFIZER INC. $51.56 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706669
Principal investigator 1 PFIZER INC. $98.81 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706671
Principal investigator 1 PFIZER INC. $136.28 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706673
Principal investigator 1 PFIZER INC. $9.25 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706675
Principal investigator 1 PFIZER INC. $136.28 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF RIMEGEPANT FOR THE PREVENTION OF MIGRAINE IN ADULTS WITH A HISTORY OF INADEQUATE RESPONSE TO ORAL PREVENTIVE MEDICATIONS No dispute reported 06/30/2026 1228706771
Principal investigator 1 PFIZER INC. $107.59 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706773
Principal investigator 1 PFIZER INC. $98.81 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706775
Principal investigator 1 PFIZER INC. $76.88 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706815
Principal investigator 1 PFIZER INC. $89.02 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706817
Principal investigator 1 PFIZER INC. $125.48 12/06/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706819
Principal investigator 1 ModernaTX, Inc. $1,424.00 12/01/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975723
Principal investigator 1 ModernaTX, Inc. $9,499.05 11/27/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975677
Principal investigator 1 ModernaTX, Inc. $644.10 11/27/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975701
Principal investigator 1 ModernaTX, Inc. $686.85 11/27/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975735
Principal investigator 1 ModernaTX, Inc. $3,824.70 11/27/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975737
Principal investigator 1 PFIZER INC. $504.00 11/26/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228728883
Principal investigator 1 ModernaTX, Inc. $136.60 11/20/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975703
Principal investigator 1 ModernaTX, Inc. $199.56 10/29/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975755
Principal investigator 1 ModernaTX, Inc. $2,060.55 10/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975693
Principal investigator 1 ModernaTX, Inc. $3,762.00 10/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975699
Principal investigator 1 ModernaTX, Inc. $2,898.45 10/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $168.00 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $246.40 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252476
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,429.40 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252482
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,090.60 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252518
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,311.60 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252550
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $989.80 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252552
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $79.80 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252554
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $229.60 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252558
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,857.00 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252568
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $26,413.38 10/16/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250889
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,000.00 10/09/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249056
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,200.00 10/09/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249086
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,041.00 10/09/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184249104
Principal investigator 1 ModernaTX, Inc. $1,424.00 10/08/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975695
Principal investigator 1 PFIZER INC. $2,760.44 10/08/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228740362
Principal investigator 1 ModernaTX, Inc. $1,373.70 09/29/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975727
Principal investigator 1 ModernaTX, Inc. $6,118.95 09/29/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975731
Principal investigator 1 ModernaTX, Inc. $3,657.50 09/29/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975741
Principal investigator 1 ModernaTX, Inc. $1,424.00 09/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975687
Principal investigator 1 ModernaTX, Inc. $1,424.00 09/17/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975659
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $7,054.00 09/10/2025 Non-covered Recipient Entity
Clinvest Headlands Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067609
Principal investigator 1 ModernaTX, Inc. $1,373.70 08/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975661
Principal investigator 1 ModernaTX, Inc. $4,535.30 08/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975697
Principal investigator 1 ModernaTX, Inc. $5,277.25 08/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975743
Principal investigator 1 ModernaTX, Inc. $5,796.90 08/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975751
Principal investigator 1 ModernaTX, Inc. $217.36 08/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006721
Principal investigator 1 ModernaTX, Inc. $862.04 08/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006769
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,045.00 08/27/2025 Non-covered Recipient Entity
Clinvest Headlands Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067067
Principal investigator 1 PFIZER INC. $150.00 08/13/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228751889
Principal investigator 1 PFIZER INC. $2,657.62 08/13/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228753773
Principal investigator 1 PFIZER INC. $1,500.00 08/12/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228752961
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,601.26 08/06/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431198
Principal investigator 1 ModernaTX, Inc. $1,055.45 07/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975715
Principal investigator 1 ModernaTX, Inc. $1,003.20 07/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975745
Principal investigator 1 PFIZER INC. $1,604.00 07/11/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228782542
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,750.00 07/09/2025 Non-covered Recipient Entity
CLINVEST RESEARCH
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185549387
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $300.00 07/02/2025 Non-covered Recipient Entity
Clinvest Headlands Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066967
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $180.00 07/02/2025 Non-covered Recipient Entity
Clinvest Headlands Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066969
Principal investigator 1 ModernaTX, Inc. $9,499.05 06/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975669
Principal investigator 1 ModernaTX, Inc. $1,288.20 06/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975671
Principal investigator 1 ModernaTX, Inc. $2,779.70 06/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975673
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $927.48 06/25/2025 Non-covered Recipient Entity
Clinvest Research LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246431192
Principal investigator 1 ModernaTX, Inc. $27,441.70 06/18/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975679
Principal investigator 1 ModernaTX, Inc. $6,118.95 06/18/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975733
Principal investigator 1 ModernaTX, Inc. $3,991.90 06/18/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975753
Principal investigator 1 ModernaTX, Inc. $4,000.00 06/18/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006739
Principal investigator 1 ModernaTX, Inc. $8,189.38 06/18/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006771
Principal investigator 1 ModernaTX, Inc. $2,700.00 06/18/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006777
Principal investigator 1 PFIZER INC. $75.00 06/17/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706267
Principal investigator 1 PFIZER INC. $75.00 06/17/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706562
Principal investigator 1 PFIZER INC. $250.00 06/17/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706570
Principal investigator 1 PFIZER INC. $75.00 06/17/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706657
Principal investigator 1 PFIZER INC. $250.00 06/17/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706659
Principal investigator 1 PFIZER INC. $75.00 06/17/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706661
Principal investigator 1 PFIZER INC. $1,500.00 06/13/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228775898
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,631.00 06/13/2025 Non-covered Recipient Entity
Clinvest Research LLC
INSPIRE LTE study No dispute reported 06/30/2026 1246431204
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $861.00 06/12/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206263
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $7,950.93 06/11/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431200
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $11,150.00 06/05/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812440
Principal investigator 1 PFIZER INC. $3,500.00 06/05/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228775585
Principal investigator 1 PFIZER INC. $1,600.00 06/05/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228775679
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $300.00 06/04/2025 Non-covered Recipient Entity
Clinvest Headlands Llc
LX9211 No dispute reported 06/30/2026 1248066687
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $585.00 06/04/2025 Non-covered Recipient Entity
Clinvest Headlands Llc
LX9211 No dispute reported 06/30/2026 1248066689
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $247.49 06/03/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812438
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $176.02 06/02/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431220
Principal investigator 1 ModernaTX, Inc. $4,117.30 05/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975691
Principal investigator 1 ModernaTX, Inc. $8,443.60 05/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975705
Principal investigator 1 ModernaTX, Inc. $16,102.50 05/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975739
Principal investigator 1 ModernaTX, Inc. $5,779.80 05/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006731
Principal investigator 1 ModernaTX, Inc. $350.00 05/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006737
Principal investigator 1 ModernaTX, Inc. $19,483.36 05/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006741
Principal investigator 1 ModernaTX, Inc. $71,118.30 05/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006755
Principal investigator 1 ModernaTX, Inc. $850.00 05/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006761
Principal investigator 1 ModernaTX, Inc. $675.00 05/21/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006763
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $45.50 05/19/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431188
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $130.00 05/19/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.60 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $861.00 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194797
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $58.80 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194809
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $861.00 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194813
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,722.00 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,722.00 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194821
Principal investigator 1 Eli Lilly and Company $6,482.00 05/12/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) No dispute reported 06/30/2026 1187877575
Principal investigator 1 ModernaTX, Inc. $264.00 05/12/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006775
Principal investigator 1 ModernaTX, Inc. $3,333.20 05/09/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006725
Principal investigator 1 ModernaTX, Inc. $325.00 05/09/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006747
Principal investigator 1 ModernaTX, Inc. $264.00 05/09/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006751
Principal investigator 1 PFIZER INC. $1,850.00 05/09/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228771984
Principal investigator 1 PFIZER INC. $75.00 05/08/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228762733
Principal investigator 1 PFIZER INC. $75.00 05/08/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228765322
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $38.52 05/08/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431218
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $724.00 05/06/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812436
Principal investigator 1 Eli Lilly and Company $10,935.00 05/05/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187878053
Principal investigator 1 Eli Lilly and Company $11,719.69 05/05/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187879777
Principal investigator 1 Eli Lilly and Company $17,198.50 05/05/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A STUDY OF TIRZEPATIDE (LY3298176) IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES SWITCHING FROM DULAGLUTIDE (SURPASS-SWITCH) (SURPASS-SWITCH) No dispute reported 06/30/2026 1187883484
Principal investigator 1 ABBVIE INC. $2,300.00 05/01/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202480839
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 05/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724143
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724145
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724147
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724149
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724151
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 05/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724153
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $145.00 05/01/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812430
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $175.00 05/01/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812432
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,100.00 05/01/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812434
Principal investigator 1 ABBVIE INC. $800.00 04/30/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202480603
Principal investigator 1 Eli Lilly and Company $154.59 04/30/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187878225
Principal investigator 1 ModernaTX, Inc. $1,055.45 04/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975667
Principal investigator 1 ModernaTX, Inc. $14,492.25 04/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975675
Principal investigator 1 ModernaTX, Inc. $3,741.10 04/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975725
Principal investigator 1 ModernaTX, Inc. $53,877.50 04/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006729
Principal investigator 1 ModernaTX, Inc. $23,119.20 04/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006791
Principal investigator 1 ModernaTX, Inc. $28,197.52 04/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006793
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,340.00 04/25/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431210
Principal investigator 1 ABBVIE INC. $5,000.00 04/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202479259
Principal investigator 1 ModernaTX, Inc. $325.00 04/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006719
Principal investigator 1 ModernaTX, Inc. $264.00 04/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006781
Principal investigator 1 PFIZER INC. $1,823.60 04/24/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228779192
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 04/23/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724155
Principal investigator 1 Boehringer Ingelheim International GmbH $438.00 04/23/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724157
Principal investigator 1 Boehringer Ingelheim International GmbH $17.40 04/23/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724159
Principal investigator 1 Boehringer Ingelheim International GmbH $13.80 04/23/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724161
Principal investigator 1 PFIZER INC. $3,000.00 04/18/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706566
Principal investigator 1 PFIZER INC. $2,500.00 04/18/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706665
Principal investigator 1 PFIZER INC. $2,000.00 04/18/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706667
Principal investigator 1 PFIZER INC. $233.34 04/17/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777094
Principal investigator 1 PFIZER INC. $150.00 04/17/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777398
Principal investigator 1 PFIZER INC. $3,750.00 04/17/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777552
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,687.00 04/11/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812426
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $18,923.00 04/11/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812428
Principal investigator 1 PFIZER INC. $5,567.90 04/10/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228776609
Principal investigator 1 PFIZER INC. $3,500.00 04/10/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228777402
Principal investigator 1 ModernaTX, Inc. $15,028.00 04/09/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006779
Principal investigator 1 Eli Lilly and Company $1,983.29 04/08/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187879775
Principal investigator 1 PFIZER INC. $1,500.00 04/04/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228775985
Principal investigator 1 PFIZER INC. $47.25 04/04/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228777877
Principal investigator 1 PFIZER INC. $780.00 04/04/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228778335
Principal investigator 1 Eli Lilly and Company $2,129.72 04/03/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187879531
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $2,999.95 04/02/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431206
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $91.00 04/02/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431208
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724131
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724133
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724135
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724137
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 04/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724139
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 04/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724141
Principal investigator 1 ModernaTX, Inc. $50.00 04/01/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006743
Principal investigator 1 Janssen Research & Development, LLC $640.00 03/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175433916
Principal investigator 1 Janssen Research & Development, LLC $5,626.00 03/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Phase 4 Multi Center Randomized Double blind Placebo controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio naive Participants with Active Psoriatic Arthritis Axial Disease No dispute reported 06/30/2026 1175433921
Principal investigator 1 ModernaTX, Inc. $3,166.35 03/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975689
Principal investigator 1 ModernaTX, Inc. $3,741.10 03/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975713
Principal investigator 1 ModernaTX, Inc. $11,271.75 03/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975759
Principal investigator 1 ModernaTX, Inc. $25,352.08 03/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006735
Principal investigator 1 ModernaTX, Inc. $9,051.42 03/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006757
Principal investigator 1 ModernaTX, Inc. $34,678.80 03/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006765
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $66,428.00 03/21/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812424
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $38.80 03/19/2025 Non-covered Recipient Entity
Clinvest Headlands Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066799
Principal investigator 1 ModernaTX, Inc. $300.00 03/19/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ?50 Years of Age No dispute reported 06/30/2026 1252975681
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,164.42 03/19/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174564
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,594.38 03/17/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431202
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $525.00 03/12/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812408
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $435.00 03/12/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812410
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,000.00 03/12/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812412
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $910.00 03/12/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812414
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $350.00 03/12/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812416
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,961.83 03/12/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812418
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 03/12/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812420
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $435.00 03/12/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812422
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $68.75 03/12/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,164.42 03/11/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170876
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,640.78 03/10/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431194
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $38.52 03/07/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431214
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,763.24 03/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156740
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724107
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724109
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724111
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724113
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 03/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724115
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 03/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724117
Principal investigator 1 ModernaTX, Inc. $171.60 02/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006749
Principal investigator 1 ModernaTX, Inc. $114.40 02/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006787
Principal investigator 1 ModernaTX, Inc. $1,713.80 02/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975655
Principal investigator 1 ModernaTX, Inc. $15,458.40 02/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975657
Principal investigator 1 ModernaTX, Inc. $1,373.70 02/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975707
Principal investigator 1 ModernaTX, Inc. $13,421.60 02/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975729
Principal investigator 1 ModernaTX, Inc. $4,075.50 02/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975749
Principal investigator 1 ModernaTX, Inc. $17,942.65 02/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975761
Principal investigator 1 ModernaTX, Inc. $37,568.70 02/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006727
Principal investigator 1 ModernaTX, Inc. $51,291.38 02/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006773
Principal investigator 1 ModernaTX, Inc. $28,770.56 02/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006785
Principal investigator 1 PFIZER INC. $528.68 02/27/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228765422
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 02/25/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724125
Principal investigator 1 Boehringer Ingelheim International GmbH $221.10 02/25/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724127
Principal investigator 1 Eli Lilly and Company $6,567.00 02/25/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187878293
Principal investigator 1 ModernaTX, Inc. $3,355.40 02/19/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975685
Principal investigator 1 PFIZER INC. $5,000.00 02/19/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228706663
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,876.64 02/18/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154220
Principal investigator 1 ABBVIE INC. $1,500.00 02/13/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202451269
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,372.00 02/13/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
Obesity Long term safety in patients with CV risk No dispute reported 06/30/2026 1220812406
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,876.64 02/11/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152966
Principal investigator 1 Eli Lilly and Company $62.50 02/07/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187877581
Principal investigator 1 ModernaTX, Inc. $7,500.00 02/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ?50 Years of Age No dispute reported 06/30/2026 1252975683
Principal investigator 1 ModernaTX, Inc. $10,800.00 02/05/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975665
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,810.67 02/05/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431196
Principal investigator 1 Eli Lilly and Company $376.95 02/04/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187882252
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724095
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724097
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724099
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724101
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 02/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724103
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 02/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724105
Principal investigator 1 Eli Lilly and Company $298.59 01/31/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187878143
Principal investigator 1 Eli Lilly and Company $195.00 01/31/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187879523
Principal investigator 1 Eli Lilly and Company $293.55 01/30/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) No dispute reported 06/30/2026 1187879519
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,529.44 01/29/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149886
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 01/27/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724119
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 01/27/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724121
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 01/27/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724123
Principal investigator 1 Eli Lilly and Company $652.00 01/27/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187878049
Principal investigator 1 ModernaTX, Inc. $130,860.60 01/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975663
Principal investigator 1 ModernaTX, Inc. $29,552.60 01/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975719
Principal investigator 1 ModernaTX, Inc. $14,170.20 01/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975721
Principal investigator 1 ModernaTX, Inc. $11,620.40 01/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975747
Principal investigator 1 ModernaTX, Inc. $4,639.80 01/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252975757
Principal investigator 1 ModernaTX, Inc. $28,968.16 01/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006723
Principal investigator 1 ModernaTX, Inc. $33,500.61 01/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006759
Principal investigator 1 ModernaTX, Inc. $14,654.68 01/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006767
Principal investigator 1 ModernaTX, Inc. $2,754.05 01/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006783
Principal investigator 1 ModernaTX, Inc. $28,899.00 01/27/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006789
Principal investigator 1 PFIZER INC. $12,850.00 01/25/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY WITH AN OPENLABEL EXTENSION TO INVESTIGATE RIMEGEPANT IN MIGRAINE PREVENTION IN ADOLESCENTS 12 TO LESS THAN 18 YEARS OF AGE WITH CHRONIC MIGRAINE No dispute reported 06/30/2026 1228799154
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,250.00 01/24/2025 Non-covered Recipient Entity
Clinvest Headlands Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066867
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,430.00 01/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149340
Principal investigator 1 Eli Lilly and Company $381.62 01/22/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187879277
Principal investigator 1 Eli Lilly and Company $171.00 01/21/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
PEDIATRIC OPTIONS FOR MIGRAINE RELIEF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE PIONEER PEDS1 No dispute reported 06/30/2026 1187880099
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,099.44 01/21/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149022
Principal investigator 1 Eli Lilly and Company $18,851.58 01/17/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187877191
Principal investigator 1 ModernaTX, Inc. $1,989.00 01/17/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006733
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $4,142.53 01/14/2025 Non-covered Recipient Entity
Clinvest Headlands Llc
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066865
Principal investigator 1 Eli Lilly and Company $13,078.00 01/13/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187877187
Principal investigator 1 Eli Lilly and Company $52.16 01/13/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187879779
Principal investigator 1 ModernaTX, Inc. $85.80 01/13/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006753
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $196.21 01/10/2025 Non-covered Recipient Entity
Clinvest Research LLC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431212
Principal investigator 1 Eli Lilly and Company $141,603.00 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187877577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $117.60 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145802
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $861.00 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145804
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $112.00 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145806
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $119.00 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145808
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $119.00 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145810
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,461.00 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145812
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $278.60 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145814
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,065.64 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145816
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,164.42 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145818
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $562.80 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145820
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $119.00 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145822
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $861.00 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145824
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $117.60 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145826
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,430.00 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145828
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $117.60 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184145830
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,250.00 01/06/2025 Non-covered Recipient Entity
JEM HEADLANDS LLC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185549389
Principal investigator 1 ModernaTX, Inc. $1,500.00 01/03/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253006745
Principal investigator 1 ABBVIE INC. $2,978.25 01/02/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202434864
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724085
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724087
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724089
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724091
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 01/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724093
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 01/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724129